Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of the Effect of First-line Treatment With Avastin+Xelox, Followed by Avastin+Tarceva, on Progression-free Survival in Patients With Metastatic Colorectal Cancer

NCT01135498 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01135498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01135498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of the Effect of First-line Treatment With Avastin+Xelox, Followed by Avastin+Tarceva, on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2006
Completion date
April 30, 2010
Enrollment
90 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer